Acclinate and HCN Global Forge Strategic Partnership to Enhance Clinical Research Diversity

Acclinate and HCN Global Partner to Boost Hispanic, Latino Trial Diversity

Acclinate and HCN Global have launched a strategic partnership to improve clinical research access and representation for Hispanic and Latino communities. The collaboration leverages Acclinate's NOWINCLUDED platform and HCN Global's established networks to address underrepresentation in clinical trials. For BD and strategy teams, the deal establishes a new reference point in the multicultural patient recruitment space — pairing digital scale with community-embedded trust to meet tightening FDA diversity expectations.

Key Takeaways

• Acclinate and HCN Global announced a strategic, research-ready partnership on February 23, 2024, targeting increased clinical trial representation for Hispanic and Latino communities.
• The collaboration pairs Acclinate's NOWINCLUDED digital platform — with over 220,000 members — with HCN Global's grassroots networks, including La Red Hispana and LatinEQUIS.
• Together, the two organizations will deploy trusted digital and grassroots activations across Black/African American and Hispanic/Latino communities.
• The initiative addresses documented underrepresentation of Hispanic and Latino populations in clinical research, a gap peer-reviewed analysis has identified as modifiable.
• The deal positions sponsors to accelerate diverse enrollment without building community-engagement infrastructure from scratch.

What Does the Acclinate–HCN Global Partnership Actually Look Like?

Acclinate and HCN Global unveiled their partnership on February 23, 2024, framing it as a strategic, research-ready collaboration designed to bridge gaps in multicultural health research. The deal brings together two organizations with complementary strengths: Acclinate contributes its NOWINCLUDED platform, which has amassed over 220,000 members, while HCN Global brings established community networks including La Red Hispana and LatinEQUIS.

The combined effort will deploy both digital activations and grassroots outreach across Black/African American and Hispanic/Latino communities. The partnership is structured to be research-ready from launch, meaning pharmaceutical sponsors can engage the combined infrastructure for active enrollment campaigns without building community trust from scratch. For sponsors conducting trials in therapeutic areas with known disparities in Hispanic and Latino participation, the alliance offers a turnkey channel to access pre-engaged, diverse patient populations.

Why Is Hispanic and Latino Underrepresentation in Clinical Trials a Modifiable Problem?

The rationale behind the deal is grounded in well-documented enrollment gaps. Comparative analyses of clinical research activity in Latin America illustrate both underrepresentation and its modifiable nature — meaning the disparity is not an intractable problem but one that targeted infrastructure can address. Peer-reviewed research confirms that Hispanic and Latino populations remain underrepresented in clinical trials despite bearing disproportionate burdens in several disease categories.

For pharmaceutical companies, the business case is tightening. The FDA has increased pressure on sponsors to present diversity action plans, and payers are beginning to scrutinize whether trial populations reflect real-world demographics. A partnership that can demonstrably accelerate enrollment of Hispanic and Latino participants — while maintaining retention and protocol compliance — removes a persistent operational bottleneck in late-phase development.

How Should BD and Strategy Teams Evaluate This Type of Partnership?

This deal presents a concrete opportunity for pharmaceutical companies seeking to improve the diversity of their clinical trial participants. By combining a digital-first engagement platform with community-embedded outreach, Acclinate and HCN Global are offering sponsors a model that addresses both the recruitment and trust barriers that have historically limited Hispanic and Latino enrollment.

For BD and strategy teams, the deal highlights a growing trend toward specialized patient recruitment and engagement platforms focused on underserved communities. The multicultural clinical trial recruitment space has attracted increasing investment, and partnerships like this one raise the competitive bar — sponsors will expect similar capabilities from other vendors. Companies evaluating CROs or recruitment partners should now benchmark against models that combine digital scale with community credibility.

Teams should assess the combined platform's reach, enrollment speed, retention rates, and ability to meet FDA diversity benchmarks. The Acclinate–HCN Global model sets a new reference point for what sponsors should expect from multicultural recruitment partners.

What Is the Competitive Impact on the Multicultural Recruitment Space?

The partnership signals a sharpened market focus on specialized multicultural patient recruitment. As FDA diversity guidance becomes more prescriptive, sponsors need vendors that can deliver representative enrollment at speed — not just consult on the problem. Acclinate and HCN Global have combined two of the industry's most trusted multicultural health platforms into a single, deployable offering.

From a market access perspective, more inclusive trial data can accelerate regulatory review and strengthen health equity narratives with payers. Demonstrating that a therapy has been studied in representative populations is becoming a differentiator in formulary negotiations and FDA advisory committee presentations. Competitors in the patient recruitment space will need to demonstrate comparable community depth and digital infrastructure to remain competitive.

Frequently Asked Questions

Related coverage

• ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements
• Rusan Pharma Secures PMDA GMP Approval, Boosting Global Market Access
• Disparities in Early Access to Innovative Therapies: A Global Overview